Drug: Ibogaína

What It Is

Ibogaine is a single compound, a monoterpene indole alkaloid, extracted from the root bark of Tabernanthe iboga, a shrub used ceremonially in West Central Africa. Researchers have studied it for one purpose above all: interrupting addiction, and opioid dependence most of all.

A single large dose is reported to ease withdrawal for days; standard opioid-agonist treatment, methadone or buprenorphine, is taken daily and indefinitely. Ibogaine draws attention for two reasons. One is an early, repeated signal that it helps some people whom other treatments have failed. The other is a documented danger of sudden death from a disturbed heart rhythm.

What It Does

In an observational study of 30 people dependent on opioids, a single dose dropped withdrawal scores from 31.0 to 14.0 on a 0-to-64 scale within about three days. At one month, half reported no opioid use in the previous 30 days. Drug-use severity was still improved out to 12 months, though below the one-month peak.

A separate 12-month study followed 14 people treated legally in New Zealand. A year later they used fewer opioids and scored lower for depression. One of the 14 died during treatment.

The strongest recent work is a 2024 Stanford study of 30 male Special Operations veterans, most with mild brain injury. A single treatment of ibogaine with magnesium was followed a month later by large gains in functioning, post-traumatic stress, depression, and anxiety.

All of this evidence is the same weak quality: small, open-label, no control group. No one was blinded, everyone chose and often paid to be there, and each study was small. That combination inflates the apparent benefit. It cannot separate the drug from expectation, from the detox care given alongside, or from the natural course of withdrawal. No adequate randomized controlled trial has been completed, and the field's own reviews call the results preliminary.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

How it works

Los alcaloides iboga bloquean el canal de potasio hERG, el mecanismo detrás de la prolongación del QTModerate · risk

In plain terms

La ibogaína y sus parientes bloquean un canal cardíaco específico llamado hERG, que es la razón biológica por la que el fármaco altera el ritmo cardíaco.

In detail

En estudios celulares, la ibogaína y los alcaloides iboga relacionados bloquean el canal de potasio hERG que repolariza el corazón. Perder esa corriente alarga el intervalo QT y crea el sustrato eléctrico sobre el cual puede iniciarse un ritmo peligroso. Measured in: hERG channels expressed in cell systems. El trabajo celular mecanístico explica cómo surge el riesgo pero por sí solo no predice la dosis ni la persona en quien ocurrirá un ritmo peligroso.

The study · 1

Alper et al., hERG blockade by iboga alkaloids · Cardiovasc Toxicol 2016;16(1):14-22

Addiction

Las puntuaciones de abstinencia de opioides bajaron más de la mitad dentro de tres días, y la mitad del grupo reportó ningún consumo de opioides un mes despuésPreliminary

In plain terms

En 30 personas con dependencia de opioides, los síntomas de abstinencia bajaron más de la mitad dentro de los tres días de una única dosis de ibogaína, y un mes después la mitad reportó ningún consumo de opioides, pero no hubo grupo de comparación.

In detail

En un estudio observacional de 30 adultos con dependencia de opioides, las puntuaciones de la Escala Subjetiva de Abstinencia de Opioides bajaron de 31.0 a 14.0 en una escala de 0 a 64 dentro de aproximadamente 76 horas de una única dosis de ibogaína, y al mes 15 de 30 (50 %) reportaron ningún consumo de opioides en los 30 días anteriores, con la gravedad del consumo de drogas todavía mejorada de los 3 a los 12 meses aunque por debajo del pico del primer mes. Measured in: 30 adults with DSM-IV opioid dependence (25 men, 5 women) treated at a clinic in Mexico. What could explain it instead: Self-selection into a private overseas clinic, no comparison group, and concurrent detoxification and aftercare all sit between the drug and the outcome.. Un grupo sin control y sin cegamiento, en 30 pacientes autoseleccionados, por lo que el cambio no puede separarse de la atención de desintoxicación concurrente, la expectativa, o el curso natural de la abstinencia.

The study · 1

Brown & Alper, treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes · Am J Drug Alcohol Abuse 2018;44(1):24-36

Un único tratamiento se correspondió con un menor consumo de opioides y menores puntuaciones de depresión sostenidas durante 12 meses, y un participante murió durante el tratamientoPreliminary

In plain terms

Entre 14 personas tratadas legalmente en Nueva Zelanda, el consumo de opioides y las puntuaciones de depresión fueron menores un año después de un único tratamiento con ibogaína, pero solo 8 terminaron el estudio y una persona murió durante el tratamiento.

In detail

Entre 14 neozelandeses a quienes se dio ibogaína legal para la dependencia de opioides, la gravedad del consumo de drogas en el Índice de Gravedad de la Adicción-Lite bajó significativamente desde el inicio hasta los 12 meses en los 8 que completaron todas las entrevistas (p = 0.002), la depresión en el BDI-II también bajó (p < 0.001), y las puntuaciones de abstinencia cayeron agudamente después del tratamiento en los 14 (p = 0.015). Uno de los 14 murió durante el tratamiento. Measured in: 14 adults with opioid dependence (50% female) treated legally in New Zealand. What could explain it instead: No comparison group, heavy dropout, self-selection, and treatment providers working alongside other health professionals mean the reduction cannot be attributed to ibogaine alone.. Solo 8 de 14 completaron el seguimiento, no hubo grupo control, y un participante murió durante el tratamiento, por lo que el beneficio y el peligro provienen de la misma pequeña serie.

The study · 1

Noller et al., ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study · Am J Drug Alcohol Abuse 2018;44(1):37-46

Mood & stress

En veteranos con lesión cerebral, el funcionamiento, el TEPT, la depresión y la ansiedad mejoraron un mes después del magnesio-ibogaínaPreliminary

In plain terms

Treinta veteranos varones con lesiones cerebrales tuvieron grandes mejoras en el funcionamiento, el TEPT, la depresión y la ansiedad un mes después de un único tratamiento de magnesio-ibogaína, pero no hubo grupo control y todos sabían que habían recibido el fármaco.

In detail

En 30 veteranos varones de Operaciones Especiales con lesión cerebral traumática predominantemente leve, las puntuaciones de discapacidad mejoraron un mes después de un único tratamiento de magnesio-ibogaína (d de Cohen = 2.20), junto con grandes reducciones en el TEPT (d = 2.54), la depresión (d = 2.80) y la ansiedad (d = 2.13). El magnesio se coadministró para atenuar el riesgo cardíaco, y no se reportaron eventos adversos graves. Measured in: 30 male Special Operations Forces veterans with predominantly mild TBI (Stanford MISTIC protocol). What could explain it instead: No comparison group, self-selected veterans who traveled abroad for treatment, complementary therapies given alongside the drug, and investigator financial interests all bear on the result.. Abierto, sin grupo control, administrado junto con otras terapias, y dirigido por un equipo que posee patentes relacionadas, por lo que los tamaños del efecto muy grandes son provisionales y sin cegamiento.

Who this may not transfer to:Measured only in male Special Operations veterans. It has not been tested in women, and injury type, cardiac risk and hormonal factors differ by sex, so whether the same effect holds in women is unknown.

The study · 1

Cherian et al., magnesium-ibogaine therapy in veterans with traumatic brain injuries · Nat Med 2024;30(2):373-381

Evidence And Methods

Ningún ensayo controlado aleatorizado adecuado ha probado la ibogaína para la adicción; la evidencia de eficacia es abierta y no controladaPreliminary · mixed

In plain terms

Todavía no hay un ensayo aleatorizado adecuado de ibogaína para la adicción; todos los resultados alentadores provienen de estudios donde todos sabían que estaban recibiendo el fármaco y no había grupo de comparación.

In detail

A partir de 2024, la evidencia de eficacia humana para la ibogaína en el trastorno por uso de sustancias proviene de estudios abiertos y observacionales sin cegamiento y sin grupo control. No se ha completado ningún ensayo controlado aleatorizado adecuado, y las propias revisiones del campo califican los hallazgos como preliminares y necesitados de ensayos controlados. Measured in: the published human literature on ibogaine for substance-use disorder. Sin un grupo control aleatorizado, el tamaño de cualquier efecto verdadero es desconocido, y la expectativa y el curso natural de la adicción no pueden separarse del fármaco.

The study · 1

Cherian et al., psychedelic therapy: a primer for primary care clinicians, ibogaine · Am J Ther 2024;31(2):e133-e140

The same studies that report benefit also record deaths.

A review of all known fatalities outside West Central Africa from 1990 to 2008 found 19 people who died within 1.5 to 76 hours of taking ibogaine, most of them with preexisting heart disease or other drugs also present.

How It Works

Ibogaine does not act on one clean target. It binds serotonin and opioid receptors, NMDA glutamate receptors, sigma receptors, and nicotinic receptors. The liver converts it into a long-lived metabolite, noribogaine, that stays active for days and carries much of the drug's continuing effect. No single one of these actions has been shown to be why craving falls, so the mechanism behind the addiction signal is still open.

The cardiac action is better understood. Ibogaine and its metabolite block the hERG potassium channel, the current that resets each heart cell after a beat. Cut that current and the electrical recovery lengthens, seen on an electrocardiogram as a prolonged QT interval. A long QT is the setting where a chaotic, sometimes fatal rhythm called torsades de pointes can start. The effect grows with the dose and worsens when the heart is already stressed or potassium or magnesium is low. That dose-related danger is why the Stanford protocol pairs ibogaine with magnesium.

What Happens in the Body

1The acute experience

A large dose produces many hours of a dreamlike, waking state, often with vivid imagery, over roughly a day, followed by a long period of reduced sleep. This is the window in which withdrawal is reported to ease. It also overlaps the window in which the dangerous heart-rhythm changes occur, which is why the research settings that use it keep a person on continuous cardiac monitoring.

2The lingering metabolite

Because noribogaine persists for days, part of any lasting effect on craving is attributed to it. The hERG blockade, and the QT prolongation with it, also continues past the acute experience.

3The heart under load

A prolonged QT is where a fatal arrhythmia can start. The danger is greatest with existing heart disease, low potassium or magnesium, other QT-prolonging drugs on board, or a large or repeated dose.

The Legal Position

Ibogaine is Schedule I in the United States, the most restricted category. Outside authorized research its use is illegal, and it is not an approved treatment anywhere in the country.

Most human experience comes from clinics in Mexico, in parts of Central America and the Caribbean, and a few other countries. They operate with little or no medical regulation, varying widely in whether they screen the heart before treatment or monitor it during. New Zealand is unusual in permitting ibogaine under a controlled arrangement, which is why one of the better follow-up studies could be done there.

Go Deeper

• Psychedelics in mental health: the wider group of supervised, trial-stage compounds that ibogaine sits within, from psilocybin to MDMA.
• Meditation and mindfulness: a low-risk way to work with a craving or distressed mind that you can start on your own, and the grounding practice the Chinese medicine view points to first.
• Purpose and meaning: the sense of meaning that steadies a person through recovery, approached as a practice in its own right.

The Chinese Medicine View

Chinese medicine has a long-standing frame for intense altered states and for the pull of a substance, and it treats both with caution. The Heart is said to house the Shen, the spirit and consciousness. Clear thought, steady emotion, and settled sleep are read as signs of a rooted Shen. A mind overwhelmed by vivid imagery, disoriented or agitated, is read as a disturbance of the Shen. The classical instinct is to calm and anchor such a state.

A long, overwhelming drug experience could be seen as forcibly stirring the Shen. The tradition would approach that with great care, especially in someone depleted by years of addiction, and especially where the Heart itself carries the physical risk. Addiction, in this frame, is often read as an empty state a person tries to fill, and the classical response is to nourish and root it. The wider preventive tradition of Yang Sheng, nourishing life, would put grounding practices and steady support first.

Cautions For This Practice

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

A la ibogaína le han seguido alteraciones fatales del ritmo cardíaco; una revisión encontró 19 muertes poco después de tomarla

Una revisión sistemática de todas las muertes conocidas fuera de África Central Occidental de 1990 a 2008 encontró a 19 personas (15 hombres, 4 mujeres, de 24 a 54 años) que murieron dentro de 1.5 a 76 horas de tomar ibogaína. Las afecciones médicas preexistentes, principalmente cardiovasculares, y/o una o más drogas de abuso explicaron o contribuyeron a la muerte en 12 de los 14 casos con datos postmortem adecuados. Una serie de casos cuenta muertes sin un denominador, por lo que no puede dar una tasa, pero establece que ocurren desenlaces fatales, más a menudo cuando hay enfermedad cardíaca u otras drogas presentes.Alper et al., fatalities temporally associated with the ingestion of ibogaine

La ibogaína prolonga el intervalo QT y puede desencadenar alteraciones del ritmo cardíaco potencialmente mortales

Una revisión de los efectos cardíacos de la ibogaína reporta que prolonga el intervalo QT y se ha vinculado con informes acumulados de arritmia potencialmente mortal y muerte súbita, un efecto rastreado hasta el bloqueo del canal cardíaco de potasio hERG, con el metabolito de vida larga noribogaína conllevando la misma acción. Una revisión narrativa reúne informes existentes, sin probar el riesgo en un grupo definido, por lo que describe el peligro sin cuantificar con qué frecuencia ocurre.Koenig & Hilber, the anti-addiction drug ibogaine and the heart: a delicate relation

Ibogaine has caused fatal cardiac arrhythmias

Anyone with a heart condition, a long-QT tendency, low potassium or magnesium, or other QT-prolonging medication is at serious risk. This page carries no dosing, no sourcing, and no instructions for use.

The interactions that raise the danger

The cardiac risk climbs when ibogaine is combined with other drugs that prolong the QT interval, including some antidepressants, antipsychotics, and antibiotics, and when potassium or magnesium is low. Because ibogaine also acts on serotonin and opioid systems, combining it with opioids or serotonergic medication carries its own hazards. Anyone on medication is in territory where these interactions have caused deaths.

The evidence is a signal, not a settled treatment

The results that draw people to ibogaine come from small, uncontrolled studies, so the true size of the benefit is unknown. Treatments with a randomized-trial base exist, and clinical trials are recruiting.

Ibogaine shows an early signal for a problem that current treatments often fail, and it carries a documented risk of sudden cardiac death. Weigh the evidence at its real, preliminary strength. Treat the cardiac risk as the central fact. For your own care, talk to a qualified clinician.

Common Questions

Does ibogaine work for opioid addiction?

The early evidence points that way, with one heavy caveat: it has never been through a randomized trial. A single dose can interrupt use for months in some people, even where standard treatments have failed. But the studies are small and uncontrolled. That leaves ibogaine a preliminary signal, well short of a proven treatment.

Why is ibogaine dangerous?

Because it can stop the heart. Ibogaine lengthens the heart's electrical recovery, and in the wrong conditions that can tip into a fatal rhythm. The danger climbs in anyone with existing heart disease, in anyone whose potassium or magnesium runs low, in anyone on other QT-prolonging medication, and at higher doses.

Is ibogaine legal?

Not in the United States, where it is Schedule I and no clinic may offer it as treatment. That status does more than bar patients. It makes the controlled trials the field keeps asking for slow and costly to run, so the evidence stays thin in part because of the law itself. Most use happens in clinics abroad with little oversight.

What is the Stanford veterans study, and does it change the picture?

It is the most rigorous recent work, and it is still preliminary. In the 2024 Stanford study, 30 veterans given ibogaine with magnesium improved markedly a month later. What it cannot do is settle the question. With no control group and no blinding, expectation cannot be separated from the drug. For now ibogaine is still just a serious signal: the randomized trial that would confirm it has not been run.